Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Combined With Topotecan in Small Cell Lung Cancer
NCT04073550Phase 3Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anlotinib in small cell lung cancer (SCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
anlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04073550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04073550.